Vaxart delivered meaningful top-line progress in QQ2 2024, highlighted by first-time quarterly revenue of $6.4 million driven predominantly by BARDA activity under Project NextGen. Despite the revenue uptick, the company remains unprofitable with a substantial R&D and SG&A burden. R&D and operating expenses totaled $22.7 million for the quarter, producing an EBITDA of -$13.6 million and a net loss of -$16.5 million. Management emphasizes runway extension into 2026 via BARDA funding for its COVID-19 oral vaccine program and ongoing discussions with the FDA on norovirus, underscoring a government-backed near-term growth cadence more than immediate profitability. The company’s cash and equivalents balance stood at $43.3 million at quarter-end, with a separate BARDA inflow of approximately $64.7 million post-quarter, supporting study startup for the Phase 2b COVID trial. In aggregate, VXRT’s near-term catalysts hinge on (1) initiation of the Phase 2b trial for the oral COVID-19 vaccine (targeting ~10,000 adults) subject to FDA alignment, (2) continued constructive FDA dialogue on norovirus, and (3) the ability to convert BARDA funding into timely program milestones. The investment thesis rests on a differentiated mucosal vaccine platform with potential cross-reactive protection, balanced against execution risk, regulatory risk, and the company’s ongoing cash burn.